Option chain shows key data for Mainz Biomed's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Mainz Biomed.

Mainz Biomed (NASDAQ:MYNZ) Stock, Option Chain

Mainz Biomed

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ALGN

BKTI

CRSP

HSIC

MYNZ

XRAY

This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Screenshot 2024-12-19 at 7.13.05 PM

Biotech

General

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Man at computer, Business,Finance,Data,Analytics,Graph,Chart,Report,,Man,Using,Laptop

Large Cap

Health Care

Contracts

Stock Split

Movers

Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for faster, accurate results.

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Mainz Biomed NV

Press Releases

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Mainz Biomed Expands into Switzerland with labor team w

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aditxt

AIM ImmunoTech

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

BioCardia

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ernexa Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Ocean Biomedical

PharmaCyte Biotech

Portage Biotech

Plus Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

Maxim Group

JonesTrading

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Screenshot 2024-11-11 at 7.48.49 PM

What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer

Screenshot 2024-10-04 at 11.57.48 PM

Interview

Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early

Screenshot 2024-09-04 at 5.52.15 PM

Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool

Screenshot 2024-08-30 at 2.55.26 PM

Emerging Markets

Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test

Screenshot 2024-08-30 at 6.27.59 PM

EXAS

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Screenshot 2024-07-30 at 7.23.29 PM

Mainz Biomed&#39;s (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status

Screenshot 2024-06-20 at 6.58.26 PM

Mainz Biomed&#39;s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Comments

Mainz Biomed

Mainz Biomed (MYNZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga